Daiichi Sankyo Optimistically Ramping Up For Prasugrel Launch

Daiichi Sankyo CEO Takashi Shoda acknowledged during the company's third quarter results call that the delay in U.S. FDA approval of Effient (prasugrel), a novel platelet inhibitor that the company filed jointly with Eli Lilly in December 2007, has negatively affected the company net sales forecast